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Abstract
Microparticles (MPs) could be considered biomarkers of cell damage and activation as well as novel signalling
structures. Since rheumatoid arthritis (RA) is characterized by immune and endothelial activation, the main aim of
the present study was to analyse MP counts in RA patients. Citrated-blood samples were obtained from 114 RA
patients, 33 healthy controls (HC) and 72 individuals with marked cardiovascular (CV) risk without autoimmune
manifestations (CVR). MPs were analysed in platelet-poor plasma (PPP) and different subsets were identified by
their surface markers: platelet- (CD41+), endothelial- (CD146+), granulocyte- (CD66+), monocyte- (CD14+) and
Tang-derived (CD3+CD31+). Disease activity (DAS28), clinical and immunological parameters as well as traditional
CV risk factors (diabetes, hypertension, dyslipidemia and obesity) were registered from clinical records and all data
were integrated using Principal Component Analysis (PCA). Absolute MP number was increased in RA patients
compared with HC and positively correlated with traditional CV risk factors, similar to that of CVR subjects. In
addition, frequency of the different MP subsets was different in RA patients and significantly associated to disease
features. Moreover, in vitro assays revealed that MPs isolated from RA patients were able to promote endothelial
activation and exhibited detrimental effects on HMEC-I endothelial cell functionality. Circulating MPs from RAQ1
patients displayed quantitative and qualitative alterations that are the result of both disease-specific and traditional
CV risk factors. Accordingly, this MP pool exhibited in vitro detrimental effects on endothelial cells, thus supporting
their role as biomarkers of vascular damage.
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INTRODUCTION
Microparticles (MPs) are small membrane vesicles (0.1–1.0 µm)
constitutively released by many cell types under physiologic-
ally conditions, but enhanced in many pathological situations,
mainly associated with cell damage. Largely considered as inert
cell debris, recent studies have demonstrated they could have a
role in intercellular communication [1]. They have been demon-
strated to harbour nucleic acids, signalling molecules, cytokines
and even organelles, thereby supporting their active role in cell
biology [2,3]. These facts have led to more attention being fo-
cused on MPs, since they could exert different effects depending
on the conditions under they were originated as well as on the cell
type from which they have released. Accordingly, MPs exhibit an
Abbreviations: BMI, body mass index; CV, cardiovascular; CVR, cardiovascular risk; EMP, endothelial-derived MP; ESR, erythrocyte sedimentation rate; GMP, granulocyte-derived MP;
HC, healthy controls; MoMP, monocyte-derived MP; MP, microparticle; PCA, Principal Component Analysis; PMP, platelet-derived MP; PPP, platelet-poor plasma; PRP, platelet-rich plasma;
RA, rheumatoid arthritis; Tang, angiogenic T-cell; Tang-MP, Tang-derived MPs; TNFα, tumour necrosis factor α; VPD, Violet Proliferation Dye 450.
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array of surface markers derived from their parental cell that can
be used to assess their origin [4].
Increased levels of MPs have been reported in patients with
malignancies, infections, systemic inflammation, autoimmune
and vascular diseases, among other pathological states [5]. Thus,
circulating MPs have been commonly considered as biomark-
ers of injury, since they originate after cell activation and apop-
tosis, or are actively released upon specific activating receptors
signals [2,6]. This is especially relevant in the context of cardi-
ovascular (CV) disease, since MPs derived from different cell
types implicated in the etiopathology of the disease (endothelial
cells, lymphocytes, monocytes, smooth muscle cells and plate-
lets) have been found increased in patients [7,8]. Actually, MPs
from platelets and endothelial cells are proposed to play a role
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in thrombogenesis as well as in endothelial activation [9,10].
Moreover, platelet-derived MPs are known to be able to activate
neutrophils [1112], thereby promoting an innate immune activa-
tion that leads to neutrophil extracellular traps (NET) formation
[13]. These mechanisms are also involved in vascular damage,
thus supporting the link between MPs, inflammation and CV
disease. In fact, the chronic inflammation associated with many
autoimmune disorders could underlie the increased prevalence
of CV events reported in these patients [14,15]. However, the
role played by MP subsets in these situations remains unknown.
Therefore, knowledge of these events could help to identify pa-
tients at risk and improve specific therapies. Additionally, they
represent accessible and valuable biomarkers of different tissues
(especially the vasculature) that are difficult to reach and study.
Taking into account these considerations, rheumatoid arthritis
(RA), an autoimmune condition in which both immune and en-
dothelial activation can be found, provides an interesting scenario
to analyse MPs subsets. Previous evidence is limited and results
concerning disease associations and MP subsets are heterogen-
eous (reviewed in [1]). A plausible explanation to account for
these discrepancies, also found in other pathologies, is the lack
of standardized protocols to analyse MPs. Because of their small
size and the large heterogeneity of plasma MPs, most studies
are performed by flow cytometry, although other methods have
also been used. Traditionally, MPs had been identified by annexin
V-binding in their surface [16], but recent evidence has brought
into question this methodology, since annexin V-negative MPs
express specific surface markers [17,18] and have been reported
to have clinical relevance [19]. Consequently, many authors have
chosen different approaches to avoid annexin staining, such as
MP total labelling [20] or no labelling [4].
With the aim of estimating the contribution of MPs to
RA pathogenesis, this work simultaneously analysed total and
platelet-, endothelial-, granulocyte- and monocyte-derived MPs
in relation to disease-specific parameters as well as traditional
CV risk factors. In addition, since we have recently proposed a
role for angiogenic T-cells (Tang) in RA [21], we aimed to eval-
uate whether Tang-derived MPs can be found and if associations
with clinical parameters could provide new insights on this T-cell
subset. Finally, in vitro studies were performed to estimate the
potential deleterious effect of RA-MPs on vascular endothelium.
MATERIALS AND METHODS
Patients
We conducted a case–control study involving 114 RA patients
fulfilling the 2010 American College of Rheumatology RA cri-
teria, consecutively recruited from the Department of Rheum-
atology (Hospital Universitario Central de Asturias, Oviedo).
Routine clinical examination, including DAS28 calculation, was
performed at the time of sampling. Medical records were re-
vised in order to register clinical and immunological paramet-
ers, medications, traditional CV risk factors and previous CV
events. Definition and classification of CV events and traditional
risk factors (hypertension, diabetes, dyslipidemia, obesity and
smoking) were performed as previously established [22,23].
Simultaneously, 33 healthy volunteers within the similar age
range and gender than patients were recruited from the same pop-
ulation, and a group of 72 individuals with different traditional
CV risk factors were recruited from their primary care referral
centre (Table 1).
Automatized complete blood count and serum lipids analysis
were carried out for all the participants. Approval for the study
was obtained from the Regional Ethics Committee for Clinical
Investigation, in compliance with the Declaration of Helsinki.
All the participants gave written informed consent prior to study
inclusion.
Blood sampling and isolation of platelet-poor
plasma
A fasting blood sample was obtained by venipuncture in 4.5 ml
citrate-containing tubes (BD Vacutainer), which were transferred
to the laboratory and centrifuged at 3000 g for 15 min at room
temperature to obtain platelet-poor plasma (PPP) within a max-
imum of 2 h after blood collection. The resulting plasma was
divided in three aliquots and stored at −80 ◦C until analysis.
Analysis of MPs by flow cytometry
PPP aliquots were thawed at room temperature and 200 µl were
transferred into new tubes and centrifuged at 13000 rpm for
30 min at 15 ◦C. Then, the upper 180 µl were carefully dis-
carded and initial volume was restored with 0.22 µm double-
filtered PBS. To identify cell-derived MPs, a Violet Prolifera-
tion Dye 450 (VPD, BD Biosciences) staining was performed,
thus avoiding annexin V limitations [24]. Hence, 150 µl were
transferred into a new tube, brought to a final volume of 1 ml
with double-filtered PBS and 1 µl of 1 mM VPD was added.
After incubation at 37 ◦C for 15 min, staining was stopped by
placing the samples immediately on ice for 20 min. Finally,
VPD-stained MP suspensions were divided into different tubes
and pairs of antibodies were added to identify specific MP sub-
sets: anti-CD41–FITC (Immunostep, Spain) and anti-CD146–
APC (Miltenyi Biotech, Germany); anti-CD14–PE (Miltenyi)
and anti-CD66b–APC (BD); anti-CD3–APC (Immunostep) and
anti-CD31–PE (Immunostep). Antibodies were previously cent-
rifuged (13000 rpm, 10 min, 4 ◦C) in order to avoid aggregates Q2
[25]. Incubation was performed at room temperature for 15 min
and then MP suspensions were transferred into Stepcount tubes
(Immunostep), which allow absolute quantification. Tubes were
immediately processed by flow cytometry.
Samples were analysed in a FACS Canto II flow cytometer.
Forward scatter (FSC) and side scatter (SSC) were adjusted
to logarithmic gain. MP gate was designed according to latex
microbeads (Sigma–Aldrich) and confirmed with platelet-rich
plasma (PRP) [26], setting 1.1 and 0.3 µm as the upper and
lower detection limits. Below 0.3 µm, only debris seemed to
be detected after analysing double-filtered PBS. Unstained MPs
were used to set the threshold for VPD-positive signal and un-
stained negative control of VPD-stained MPs to establish specific
antibody fluorescence. No spillover between VPD and the fluoro-
chromes assayed was registered. Acquisition was performed until
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Table 1 Demographic and clinical parameters of RA patients
Categorical variables are summarized as numbers (percentage), and continuous variables as medians (interquartile range)
unless otherwise as stated ∗[median (range)]. aP value <0.01 (HC compared with RA: P=0.696). bP value <0.01 (CVR
compared with RA: P=0.460). DAS28, disease activity score (28 joints); HAQ, Health Assessment Questionnaire; RF,
rheumatoid factor; αCCP, cyclic citrullinated peptide antibody; ANA, antinuclear antibody. Differences were assessed by
Kruskal–Wallis and Dunn–Bonferroni multiple comparisons tests and chi-square test, as appropriate.
HC (n = 33) CVR (n = 72) RA patients (n = 114)
Gender (female:male) (n) 25:8 38:34a 90:24
Age at sampling (years)∗ 44.29 (23–72)b 57.41 (33–69) 55.04 (22–87)
Disease features
Disease duration (years) 4.91 (7.19)
Age at diagnosis (years) 48.41 (14.62)
Disease activity (DAS28) 3.61 (1.97)
Tender joint count 2.00 (6.00)
Swollen joint count 1.00 (4.00)
Patient global assessment (0–100) 40.00 (41.25)
ESR (mm/h) 15.50 (23.00)
Patient pain assessment (0–10) 4.00 (4.00)
HAQ (0–3) 0.87 (1.22)
RF (+) (n) 70 (61.4 %)
αCCP (+) (n) 70 (61.4 %)
ANA (+) (n) 58 (50.8 %)
Shared epitope (n) 47 (41.2 %)
Erosive disease (n) 49 (42.9 %)
Traditional CV risk factors (n)
Dyslipidaemia 40 (35.3 %)
Hypertension 38 (33.3 %)
Diabetes (Type 2) 9 (7.8 %)
Obesity (BMI >30) 22 (19.3 %)
Smoking habit 38 (33.3 %)
Number of traditional CV risk factors∗ 1.00 (0–4)
Previous CV events 18 (15.7 %)
Treatments (n)
None or NSAIDs 12 (10.5 %)
Glucocorticoids 61 (53.5 %)
Methotrexate 80 (70.1 %)
TNFα blockers 45 (39.4 %)
Tocilizumab 12 (10.5 %)
Statins 20 (17.5 %)
10000 microbeads from Stepcount tubes were acquired
(<4 min/tube) at medium rate. All samples were processed and
analysed batchwise to minimize technical variations.
Total and subset specific cell-derived MPs (absolute num-
ber/ml plasma) were calculated according to the MP counts ac-
quired, the total number of microbeads from Stepcount tubes and
the dilution performed during sample preparation.
In vitro assays with HMEC-I cells
The in vitro effects of plasma-isolated MPs on endothelium were
Q1
evaluated using HMEC-I cells. To this end, pooled MPs sus-
pensions from healthy controls (HC), cardiovascular risk (CVR)
individuals and RA patients were prepared from ten repres-
entative subjects of each group (HC: 1.85× 106 total MPs/ml,
9.3× 104 PMP/ml, 968.87 EMP/ml, 244.01 GMP/ml, 190.57
Tang-MP/ml and 3.8× 103 MoMP/ml; CVR: 2.2× 106 total
MPs/ml, 9.9× 104 PMP/ml, 500.23 EMP/ml, 172.64 GMP/ml,
227.61 Tang-MP/ml and 2.8× 103 MoMP/ml; and RA: 4.1× 106
total MPs/ml, 12.4× 104 PMP/ml, 2200.6 EMP/ml, 1024.86
GMP/ml, 829.65 Tang-MP/ml and 5.1× 103 MoMP/ml). Sim-
ilarly, age and gender distribution did not differ among groups
(P= 0.70 and P= 0.327, respectively). PPP was centrifuged
as previously described and supernatants were discarded and
replaced with HMEC-I complete medium so as to eliminate re-
sidual plasma containing soluble mediators. Then, the volume
was adjusted to obtain uniform total MPs concentration in the
different pools and serial dilutions were performed according to
the experimental design. Two different pools were prepared per
group and assayed simultaneously. HMEC-I cells were cultured
in MCDB131 medium (Sigma) supplemented with 10 % foetal
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calf serum (PAA, Belgium), 100 µg/ml streptomycin and ampi-
cillin (PAA), 2 mM glutamine (Sigma), 1 µg/ml hydrocortisone
(Sigma) and 10 ng/ml epidermal growth factor (Immunostep) in
a humidified incubator with 5 % CO2 at 37
◦C. Assays were per-
formed within the second and sixth passages.
For angiogenesis assays, 96-well plates were coated with 50 µl
of Matrigel (BD) and left 30 min at 37 ◦C for polymerization.
Then, 50000 HMEC-I cells resuspended in 100 µl of complete
medium were added to each well, followed by the addition of MPs
suspensions (50 µl) at different concentrations by duplicate. After
16 h of culture, both tube formation and branching points were
quantified on one focal plane in three no-overlapping fields per
well (27) at 40× magnification, using a Motic AE2000 (Motic)
inverted microscope equipped with a compatible digital camera
(Moticam 2000, Motic).
To assay endothelial activation, HMEC-I cells were cultured
in 24-well plates with MP suspensions at different concentra-
tions for 16 h. Then, cells were washed and stained with Fix-
able Viability dye e450 nm (eBioscience) for 30 min in the dark.
Next, cells were washed and stained with different antibodies:
anti-VEGFR2–PE (R&D), anti-CD144–APC (Milteny) and anti-
CD62E–APC (Immunostep) for 30 min at 4 ◦C. Finally, cells were
washed again to eliminate non-binding antibodies and immedi-
ately analysed by flow cytometry.
TNFα quantification
Serum aliquots were stored at −80 ◦C until cytokine measure-
ments. Tumour necrosis factor α (TNFα) serum levels were quan-
tified using a BD OptEIA kit (BD) following the manufacturer’s
instructions. The detection limit was 1.95 pg/ml.
Statistical analysis
Data are expressed as median (interquartile range) unless oth-
erwise stated. Differences between MP concentrations were as-
sessed using the Kruskal–Wallis test with Dunn–Bonferroni cor-
rection for multiple comparisons test, whereas correlations were
studied using the Spearman ranks test. TNFα effect on MPs
counts was studied by multivariate lineal regression analysis
adjusted by traditional CV risk factors. MPs counts were log-
transformed for normalization prior to regression analyses. Be-
cause of the high number of parameters studied, a Principal Com-
ponent Analysis (PCA) was performed, including traditional CV
risk factors and demographic, clinical and inflammatory paramet-
ers. The number of components retained was based on eighten-
values (>1) and loadings >0.5 were used to identify the vari-
ables comprising a component. Principal component scores were
calculated for each patient and used for multivariate regression
analysis. Results from in vitro assays were analysed by one-way
ANOVA with Dunnett post-hoc test. SPSS 19.0, R 3.0.3 and
GraphPad Prism 5.0 for Windows were used.
RESULTS
MP counts were increased in RA patients
Circulating MPs were quantified by flow cytometry in plasma
samples from 114 RA patients (Table 1), 33 HC and 72 individuals
with different traditional CV risk factors (Supplementary Table
S1). The strategy used to identify MPs is presented in Figure 1.
MP gate was set within 0.3 and 1.1 µm using latex microbeads
and PRP, with most of the detected MPs being smaller than
0.6 µm (Figure 1A). Total cell-derived MPs were defined as those
events within this gate and positive for VPD staining (Figure 1B).
Specific MPs subsets were identified by their surface mark-
ers: CD41+ (platelet-derived MPs, PMP), CD146+ (endothelial-
derived MPs, EMP), CD14+ (monocyte-derived MPs, MoMP),
CD66b+ (granulocyte-derived MPs, GMP) and CD3+CD31+
(Tang-derived MPs, Tang-MP) (Figure 1C). Gates were adjusted
by the signal provided by the negative control of VPD-stained
MPs.
Absolute counts of total MPs in patients and controls and that
of different subsets are summarized in Figure 2. Total number
of MPs was significantly increased in CVR individuals com-
pared with HC [3.14(2.6)× 106 compared with 2.10(1.23)× 106
MPs/ml] and further increased in RA patients [4.21(3.02)× 106
MPs/ml]. Although platelets were the main source of MPs among
the analysed subsets, they did not show a significant increase in
any group. However, the absolute number of MPs derived from
endothelial cells, granulocytes and Tang lymphocytes were sig-
nificantly increased as was the number of total MPs in RA pa-
tients. Accordingly, the frequency of these MP subsets out of
the total MPs was also increased in RA patients compared with
HC (EMP: 0.05(0.10) compared with 0.02(0.067)%, P= 0.029;
GMP: 0.02(0.03) compared with 0.01(0.00)%, P= 0.001; Tang-
MP: 8.16(11.70) compared with 1.20(6.76)%, P < 0.0001). Con-
versely, no differences were registered in the different MP subsets
between the CVR group and HC. Therefore, RA patients exhibit
not only a quantitative increase but also an altered MP profile.
MP profile was associated with traditional CV risk
factors and disease-specific parameters
Next, we wondered whether traditional CV risk factors and/or
disease-specific parameters could account for the MP altera-
tions detected in RA patients. Notably, total MPs number was
positively associated with some traditional CV risk factors in
both RA and CVR patients. Specifically, similar significant
correlations were detected with triglycerides (RA: r= 0.390,
P < 0.0002; CVR: r= 0.358, P= 0.012), total/high-density lipo-
protein (HDL)-cholesterol ratio (RA: r= 0.319, P= 0.004;
CVR: r= 0.298, P= 0.040) and body mass index (BMI) (RA:
r= 0.232, P= 0.021; CVR: r= 0.304, P= 0.022). Also, the
number of traditional CV risk factors correlated with total MP
counts (r= 0.221, P= 0.030). However, none of these associ-
ations were observed with any specific MP subset.
Nevertheless, the striking increase in the absolute number
and the differences in MP composition detected in RA pa-
tients could not be explained by the presence of traditional CVR
factors. Therefore, cellular damage and/or activation related to
disease specific parameters may play a role. In this sense, in-
teresting associations were found: EMP counts correlated pos-
itively with disease duration (r= 0.285, P= 0.005); GMP with
DAS28 (r= 0.271, P= 0.032), erythrocyte sedimentation rate
(ESR) (r= 0.233, P= 0.022) and age at diagnosis (r= 0.233,
P= 0.021); Tang-MP with DAS28 (r= 0.275, P= 0.007), tender
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Figure 1 Gating strategy for MP analysis
(A) Latex beads were used to calibrate FSC and SSC logarithmic gain and to design MP gate. Analysis of MP suspension
revealed that most MPs had this size. PRP sample was prepared to confirm MP gate. (B) Total MPs were defined as those
events VPD+. Threshold was adjusted with an unstained MP suspension. (C) Gating strategy for PMPs (CD41+ MPs), EMPs
(CD146+ MPs), GMPs (CD66b+ MPs), MoMPs (CD14+ MP) and Tang-MPs (CD3+ MPs were first gated and evaluated by
their CD31+ expression and those CD3+CD31+ double-positive were defined as Tang-MPs).
(r= 0.229, P= 0.026) and swollen joint counts (r= 0.306,
P= 0.003) and MoMP with RF titre (r= 0.240, P= 0.041). In-
terestingly, patients on tocilizumab treatment exhibited lower
Tang-MPs (P= 0.050) and GMPs (P= 0.011), whereas me-
thotrexate usage was related to decreased Tang-MPs counts
(P= 0.033), probably associated to the lower DAS28 (P < 0.001
and P= 0.008, respectively) found in these patients. Therapies
used in the CVR did not result in different MPs counts in any of
the subsets analysed.
All these results indicated that a large number of paramet-
ers, including traditional CV risk and disease specific factors,
accounted for total and specific MP subsets in RA patients.
Therefore, we employed a PCA to reduce this number into a
small set of components that could explain most of the vari-
ance of the MP counts. This method also provides an integrat-
ive approach for the different factors included, avoiding potential
collinearity bias and multiple testing concerns. PCA was conduc-
ted with the parameters summarized in Table 2 and all of them
exhibited communalities higher than 0.5. The Kaiser–Meyer–
Olkin test provide a good adequacy of the data (0.687) as the Bart-
lett test of sphericity (P= 10−49) did. Results of the PCA provided
four components with eigenvalues >1, which were interpreted
based on the loadings relating the variable to the component.
Thus, loadings higher than 0.5 were used to identify the variables
that define each component. As seen in Table 2, disease-specific
parameters loaded on the first component (‘rheumatic-related’),
whereas traditional CV risk factors loaded on the second com-
ponent (‘traditional CV-related’), only disease duration loaded
on the third component (‘duration-related’) as ESR did on the
fourth (‘inflammation-related’). This model explained 69.0 % of
the total variance.
Finally, we analysed whether principal components were asso-
ciated to the different MP subsets by multiple regression analysis
(Table 3), being each MP subset adjusted for the four components.
Interestingly, we found that traditional CVR factors (component
2) can predict total MPs numbers, whereas the counts of specific
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Figure 2 Total and specific MP subsets in patients and controls
Absolute number of total MPs and PMPs, EMPs, MoMPs, GMPs and Tang-MPs was analysed in 114 RA patients, 72
individuals with traditional CVR factors and 33 HC. Horizontal lines represent median and interquartile range. Differences
were assessed by Kruskal–Wallis with Dunn–Bonferroni multiple comparison tests. Kruskal–Wallis P value for each subset
is indicated at the bottom. Only significant P values from multiple comparisons tests are indicated.
Table 2 Component loadings from PCA
Variables included in the analysis and their corresponding loading on each component are shown. Variables were assigned
to each component based on loadings >0.5. Loadings in bold indicate the component on a variable loaded the highest.
Component loadings
Variable C1 C2 C3 C4
Disease duration (years) 0.123 0.330 0.580 −0.470
Tender joints count 0.774 −0.356 −0.280 0.014
Swollen joints count 0.701 −0.330 −0.255 −0.019
Health Assessment Questionaire (0–3) 0.706 0.140 0.031 −0.203
Patient pain assessment (1–10) 0.665 0.054 0.066 −0.315
Global patient assessment (1–100) 0.861 −0.002 0.037 −0.107
ESR (mm/h) 0.262 0.172 0.574 0.704
Disease activity (DAS28) 0.844 −0.104 0.135 0.360
BMI (kg/m2) 0.293 0.786 −0.126 0.055
Total/HDL colesterol ratio 0.031 0.622 −0.422 0.180
Number of traditional CV risk factors 0.068 0.715 −0.411 0.034
Age at sampling (years) 0.143 0.581 0.322 −0.050
MP subsets are only explained by disease-specific parameters
(components 1 and 3). These observations support our previous
findings.
TNFα levels correlated with Tang-MPs unless
traditional CV risk factors were present
Elevated production of TNFα, a cytokine involved in RA patho-
genesis, has been related to cell activation, apoptosis and en-
dothelial damage. Therefore, to evaluate whether it could play a
role in MP release, serum levels of this cytokine were quantified
in RA patients and HC.
In spite of the increased levels of TNFα present in RA patients
[8.42(9.12) compared with 5.35(4.25) pg/ml, P= 0.001], they
were unrelated to the total MP number (r= 0.037, P= 0.730).
Further analysis of MP subsets, showed Tang-MP counts were
slightly associated to TNFα (r= 0.171, P= 0.097), but this cor-
relation becomes relevant in RA patients without any traditional
CV risk factor (n= 24, r= 0.669, P < 0.0001). Moreover, this as-
sociation was also apparent, although at a lower level, in patients
with less than two traditional CV risk factors (n= 51, r= 0.459,
P= 0.001), and in those with less than three factors (n= 73,
r= 0.244, P= 0.038), indicating that the higher number of tra-
ditional CV risk factors, the lower TNFα contribution to MP
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Table 3 Multivariate regression analyses of MP subsets in RA patients
Multivariate regression analyses of MP subsets (as dependent variables) and the four components obtained by PCA compon-
ents (as predictors) associated with specific disease variables: rheumatic-related (Rhe-rel), traditional CV-related (tCV-rel),
disease duration-related (Dur-rel) and inflammation-related (Infl-rel). Results are expressed as β coefficient and (P value) for
each PCA component. Significant coefficients are highlighted in bold.
Variable Total MPs PMPs EMPs GMP Tang-MPs MoMPs
C1 (Rhe-rel) −0.085 (0.387) −0.007 (0.948) −0.131 (0.290) 0.296 (0.014) 0.319 (0.010) 0.209 (0.835)
C2 (tCV-rel) 0.290 (0.004) 0.100 (0.331) 0.039 (0.743) −0.107 (0.350) −0.008 (0.944) −0.105 (0.389)
C3 (Dur-rel) −0.014 (0.889) −0.017 (0.869) 0.329 (0.008) −0.053 (0.650) 0.073 (0.540) −0.173 (0.167)
C4 (Infl-rel) 0.058 (0.551) 0.061 (0.548) −0.119 (0.312) 0.091 (0.427) 0.118 (0.316) 0.164 (0.186)
release. Actually, analysing all RA patients in a multivariate re-
gression model including traditional CV risk factors, TNFα was
associated with Tang-MP counts (r= 0.259, P= 0.012). No as-
sociation with other MP subsets was found.
MPs from RA patients promoted endothelial
disturbance in vitro
Finally, since MPs have been linked to CV risk and endothelial ac-
tivation, we performed in vitro experiments to evaluate whether
circulating MPs isolated from HC, RA patients or individuals
with traditional CVR factors could affect angiogenic tube form-
ation and endothelial activation in HMEC-I cells.
Angiogenesis assays on Matrigel were conducted after adding
HC-, CVR- or RA-MP pools at different concentrations (0.5–
8× 106 MP/ml), selected according to the range of total MP
counts in controls (Figure 3A). Results showed that the number of
both branching points and tubes were dose-dependently inhibited
by RA-MPs, whereas no effect was seen with HC- or CVR-MPs
(Figure 3B). Interestingly, MPs from RA patients exhibited an
anti-angiogenic effect at 1× 106 MP/ml, a lower concentration
than they are usually found in plasma.
Additionally, MP-mediated activation of endothelial cells was
estimated analysing by flow cytometry different endothelial-
specific markers, as well as cell viability, in HMEC-I cells cul-
tured in the presence of the different MP pools (Figure 3C).
No cytotoxic effect was seen under any of the conditions tested,
thus excluding that viability could affect endothelial functional-
ity. However, we observed that RA-, but not HC- or CVR-MPs,
increased the expression of CD62E, CD144 and VEGFR2 (all
P < 0.050), thus suggesting the promotion of an activated en-
dothelial status.
Finally, to assess whether these findings could be attributed to
a specific cell-derived MP subset, the amount of each MP subset
present in the cultures was compared with the effects found on
angiogenic assays. Figure 4 shows that the detrimental effect
observed with total RA MPs was also detected when the different
subsets were analysed, but it seems to be different depending on
their cellular origin. Analysing the effects at physiological levels
(median value in HC), striking differences between RA and HC
were observed with MoMPs and PMPs but no with GMPs and
Tang-MPs, thus suggesting that the deleterious effect of Tang-
and GMP- RA MPs could be due to the increased proportion
within the total MP count, whereas MoMPs and PMPs from RA
patients could have a detrimental effect by themselves.
Therefore, MPs from RA patients are able to disturb in vitro
endothelial functionality dose-dependently, maybe due to an en-
dothelial activation, whereas HC- and CVR-MPs did not pro-
mote this effect, even at greater concentrations. These results
are a proof of concept that supports functional qualitative and
quantitative effects associated to a skewed composition of RA
MPs.
DISCUSSION
The study reported here shows relevant differences in the num-
ber and composition of circulating MPs in RA patients compared
with HC and individuals with traditional CV risk factors. Addi-
tionally, the main finding is that this altered MP pool is the result
of disease features as well as traditional CV risk factors, as was
supported using a PCA approach. This distinct profile could un-
derlie the detrimental effects exhibited by RA-MPs in endothelial
cells assays, presumably by promoting an endothelial activation
status. The results herein presented support the use of MPs as
biomarkers of endothelial damage in RA patients, with potential
use for clinicians in decision making and CV risk stratification.
In line with our results, other studies performed with RA pa-
tients showed increased MP counts, total or specific from different
cell subsets and associated with some clinical features [27–29].
However, evidence is limited and results are heterogeneous and
even contradictory, probably because of the different methodo-
logies used. We have developed a MP total labelling strategy so
as to (i) identify virtually all MPs and not only those derived
from apoptosis and (ii) avoid the technical drawbacks associated
with annexin V staining. Recent evidence suggests the relevance
of annexin V-negative MPs in many conditions. Actually, Nielsen
et al. reported that in Systemic Lupus Erythematosus patients
only annexin V-negative MPs were increased and associated with
clinical parameters [19], whereas other authors have reported
that most MPs did not express annexin V [17,18,30], so limit-
ing the study to this subset could bias the conclusions. On the
other hand, freezing steps and several other factors are thought
to affect the annexin V binding-fraction [26,31–33], thus making
the comparison between different studies difficult and emphas-
izing the need for alternative protocols. In this sense, different
reagents have been published [18,34–37] to overcome annexin V
disadvantages.
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Figure 3 In vitro effects of MPs isolated from patients and controls
HMEC-I cells were cultured alone (negative control, NC) or in the presence of MP pools at different concentrations isolated
from RA patients, individuals with traditional CVR factors or HC. (A) Representative microphotographs (×40) of HMEC-I
cells cultured on Matrigel coated plates to perform angiogenic assays. (B) Branching points and tubes numbers identified
in different cultures (n=8). (C) Flow cytometry analysis of CD62E, CD144 and VEGFR2 expression on HMEC-I cells cultured
in the presence of the different MP pools (n=4). Bars represent means+−S.D. and differences between each treatment
and the negative control were assessed with one-way ANOVA and Dunnett post-hoc test.
Because of their role in inflammation, angiogenesis and vas-
cular reactivity, MPs have been extensively studied in RA and
rheumatic diseases [1]. However, this is the first study in which
a PCA was used as an integrative tool to analyse MP counts,
thus avoiding multiple-testing concerns and supporting previous
results. This work clearly indicates that total MP counts can be
explained by traditional CV risk factors in individuals at risk
(RA and CVR subjects), but RA patients exhibited a profile of
increased MP subsets that is only explained by disease-specific
factors. Results from CVR individuals as positive CV-risk control
allows us to confirm that MP disturbances in RA are specific for
the disease itself and independent of comorbidities. Additionally,
although PCA component scores are independent in the whole
RA group, rheumatic- and traditional CV-related components
were positively correlated in the patients who had a history of
CV events (r= 0.602, P= 0.008; n= 18) but not in the CV-free
group (r= 0.032, P= 0.759), revealing the relationship between
these two features. These results are in line with recent evid-
ence about the interplay of traditional CV risk factors and dis-
ease parameters in RA [38,39]. Moreover, disease-specific factors
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Figure 4 In vitro effects analysed according to different MP subsets
The in vitro effect of MPs (measured as number of branching points) was analysed separately according to the different
subsets studied. RA MPs (triangles, grey full line) exhibited greater detrimental effect on branching point numbers than
those from HC (circles, black line) and CVR (squares, broken grey line) even at the same concentration, although differences
were observed when PMPs and MoMPs were compared with GMPs and Tang-MPs. Vertical dotted line represents the median
value found in HC.
associated with MP subsets in the present study (disease dura-
tion, DAS28 and age at diagnosis) have been associated with CV
disease in RA [38,40,41], thereby supporting the relevance of
MPs as biomarkers of endothelial activation and damage in RA
patients.
Another interesting finding of this work is the role played
by MPs derived from Tang cells, a recently-discovered T-cell
subset that enhance endothelial repair through cooperating with
endothelial progenitor cells [42]. Although no differences in the
frequency of MPs derived from T-lymphocytes were detected,
both frequency and absolute number of Tang-MPs were in-
creased in RA patients. Interestingly, this increased Tang-MP
formation could account for the decreased Tang cell counts pre-
viously reported in RA [21]. Moreover, our research revealed
a DAS28-dependent Tang-MP shedding, thus linking DAS28
with impaired endothelial repair. Actually, the disease para-
meters positively associated with Tang-MP in this work were
the same as has been found negatively associated with Tang
frequency [21]. Consequently, Tang-MPs could be considered
as a surrogate biomarker of endothelial damage and vascular
repair failure. Furthermore, the association between TNFα, a
proapoptotic cytokine increased in RA, and Tang-MPs reinforces
this hypothesis and the link between disease-specific paramet-
ers and MP release. Again, the finding that the presence of
traditional CV risk factors disturbs this association confirms
the interplay between traditional CV risk factors and disease
features.
In spite of the striking increase in total MPs in patients, there
were not differences compared with controls in the PMP counts,
suggesting that the RA-specific MP profile may not simply be
due to a general MP increase, but rather specific mechanisms tar-
geting different cell populations may be implicated. Accordingly,
no associations were detected between PMPs and PCA compon-
ents, whereas EMPs, GMPs and Tang-MPs correlated positively
with disease-related parameters. Another plausible explanation
is that therapies would interfere with platelet function, however,
no effect of the concomitant medications was observed, neither
when untreated patients (allowed to use NSAIDs) were analysed,
thus excluding a confounding effect of drug usage on platelet
activation. Hence, we could attribute these results to the ana-
lysis performed in our study. In fact, increased PMP counts in
RA were observed when annexin-V binding was used [28,29],
however, when alternative procedures were performed, opposed
results were achieved [19,29]. This lead us to hypothesize that
the total labelling protocol performed in this work could mask
the differences in Annexin V-positive PMPs due to an elevated
number of negative-events. Therefore, although possible platelet
activation during PPP isolation cannot be ruled out, our functional
assays indicated that the in vitro detrimental effects of MPs from
RA patients depend on qualitative alterations in PMPs rather
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than differences in absolute counts, contrary to was observed
with Tang- or GMPs (Figure 4).
The fact that the RA MP profile can only be explained by
disease-specific features leads us to think that these MPs may
have a role in RA pathogenesis. Recent studies analysing the
MP proteome support this idea [43]. Accordingly, differential
‘MP signature’ was found in synovial fluid from RA patients
compared with other arthritidies [44]. Thus, in this pathological
situation, MPs could be acting in a vicious circle: disease-related
cell injury could generate a RA-specific MP pool which in turn
might worsen specific clinical features, as might be damaging
vascular endothelium, with subsequent increase in CV risk. Ac-
cordingly, MPs from RA patients have been reported to be able
to modulate chemokines and cytokines from synoviocytes [45],
thus probably amplifying inflammatory responses.
Finally, the existence of a RA-specific MP profile was sup-
ported by our in vitro assays, since they revealed that effects on
endothelial cells depend on the MP pool rather than the concen-
tration (even within physiological concentrations). Specifically,
RA-MPs were able to inhibit HMEC-I Matrigel tube formation
in a dose-dependent manner, whereas MPs derived from HC and
CVR individuals failed to exhibit similar results. This detrimental
effect may be due to the promotion of endothelial activation, as
was indicated by flow cytometry analysis of endothelial markers.
In fact, endothelial activation has been associated with impaired
endothelial function in a variety of conditions [46], including
RA [47]. A role for MPs in CV disease and endothelial function
has been previously reported [48,49], but this is the first study
where MPs isolated from RA patients have been assayed. Despite
providing limited evidence, these results could support the role
of MPs as active players in RA pathogenesis, proving worthy of
further research.
However, it should be noted that not all MPs are proathero-
genic. Actually, some groups revealed anticoagulant and pro-
tective effects of some MP subsets [50–52], in contrast with
the procoagulant and deleterious results reported by others
[10,27,45,48,53]. Interestingly, these diverse effects could be at-
tributed to the exposure of different mediators, such as activated
protein C, tissue factor or von Willebrand factor among MP sub-
sets. Although these effects cannot be excluded with the actual
data, our results from in vitro assays point to a pathogenic role of
MPs in RA patients.
Some remarks about the current study should be made. First,
despite covering the same age range, HC were younger that RA
and CVR patients. However, no associations between age and MP
counts were detected in any group. Additionally, age was included
in the PCA in order to correct for potential differences. On the
other hand, the lack of a standardized protocol to determine cell-
derived MPs is the main limitation in the field of MPs. The fact
that we have developed a new protocol enabling the determination
of the total MPs could make the comparison of our results with
other studies difficult, since usually only apoptosis-derived MPs
were analysed. However, this is a common problem in the field,
and a balance between innovative methods and potential results
should be considered. Nevertheless, our findings are relatively
similar to others obtained by different methods. Finally, although
our data did not allow direct determination of the detrimental
effects of each specific MP subset, the in vitro results suggest
differences between them. Further studies are needed to confirm
this hypothesis, however, MPs separation procedures from plasma
have not been implemented yet. Furthermore, circulating MPs
are present in vivo as a (heterogeneous) group, so ‘individual’
in vitro effects of a single population need to be considered with
caution. In conclusion, the findings of the present study reveal
that RA patients exhibited not only increased MP counts but also
a qualitatively altered MP profile that is associated with disease-
specific and CV risk factors. Moreover, this MP profile could
be able to disturb vascular endothelium. In addition, increased
Tang-MPs, probably associated with the DAS28-dependent Tang
decrease, could have a role in endothelial repair failure in these
patients, thereby supporting the use of both Tang and Tang-MPs
as biomarkers of endothelial repair failure.
CLINICAL PERSPECTIVES
r It is known that the number of cell-derived microparticles
(MPs) is associated with endothelial dysfunction and impaired
vascular repair.
r RA patients exhibit a specific MP profile that is associated with
both disease-specific features and traditional CVR factors.
This specific profile could underlie the detrimental effects on
endothelial cells in vitro, presumably by promoting endothelial
activation.
r MPs could be considered as biomarkers of endothelial damage
in RA patients, with potential use for clinicians in decision
making and CV risk stratification.
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